Prostate cancer: PSA kinetics predict survival in patients treated with abirateroneNat Rev Urol. 2015 Apr 21. doi: 10.1038/nrurol.2015.87. [Epub ahead of print]doi:10.1038/nrurol.2015.87FennerAnnetteNature Reviews Urology
So Yu and her colleagues develop clinical trials to incorporate longitudinal changes in PSA with MFS and progression free survival (PFS) endpoints. In patients with nonmetastatic castrationresistant prostate cancer, a long time to MFS indicates how long a patient’s disease will remain contained on ...
Prostate cancer is the second most common malignancy and the fifth cause of cancer death in men, worldwide [1]. Despite survival improvements achieved using next generation hormonal therapies, chemotherapies or radionuclides [2], prostate cancer remains lethal at the metastatic castration resistant sta...
Prostate cancer is a disease characterized by uncontrolled growth of cells within the prostate gland. Prostate cancer is a frequently diagnosed cancer among males.
A UCLA-led study has found treatments that reduce the risk of being diagnosed with a cancer recurrence based on rising prostate-specific antigen (PSA) levels after radiotherapy, commonly referred to as biochemical recurrence, do not necessarily improve a patient's long-term overall survival. ...
The 5-year-survival rate for men of all races drops to 30% when they’re diagnosed with advanced, or metastatic, prostate cancer. Experts think prostate cancer screenings could save more Black lives than those at lower risk. That’s because there’s a strong link between midlife PSA levels...
In addition to the drop of his PSA, there is also an improvement of his Platelet Count – from 502 it came down to 300. Take note that an elevated platelet count is associated with an increased incidence of cancer and poor survival for many cancer types. ...
The FDA has granted fast track designation to ARX517 for use as a potential treatment option in patients with metastatic castration-resistant prostate cancer who experience disease progression on an androgen receptor pathway inhibitor.
the tumor microenvironment that lead to prostate cancer progression. Survivin/BIRC5/API4/EPR-1 is an inhibitor of apoptosis protein (IAP) involved in cell survival, mitosis, stress response and developmental gene expression [50]. Oncomine expression analysis of the Grasso Prostate Dataset reveals tha...
(BCR)-free survival proportion of European patients for subtype A (n = 161) versus C (n = 19).c, Kaplan–Meier plot of the cancer survival probability of European patients for subtype A (n = 82) versus C (n = 17). Forbandc, the probability estimates, 95% ...